Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Rocchetta

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Panminerva Medica|April 1, 1981
Sequential hormone-chemotherapy (MAP at high doses and CMF) in metastatic breast cancer. Preliminary resultsF Pannuti, A R Di Marco, A P Rossi, et al.
Minerva Medica|September 1, 1980
[Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses]A Martoni, G Pedelini, G Colalongo, et al.
Panminerva Medica|January 1, 1981
Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot studyF Pannuti, A P Rossi, A R Di Marco, et al.
Panminerva Medica|January 1, 1983
The prevention of the cardiotoxic effects of adriamycin by means of strophanthin. Preclinical study (chick embryo test)F Pannuti, E Piana, D Palenzona, et al.
Molecular and Cellular Endocrinology|January 13, 2001
Technical aspects of oocyte cryopreservationR Fabbri, E Porcu, T Marsella, et al.
European Journal of Cancer|April 1, 1979
Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancerF Pannuti, A Martoni, A R Di Marco, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Panminerva Medica|April 1, 1981
Sequential hormone-chemotherapy (MAP at high doses and CMF) in metastatic breast cancer. Preliminary resultsF Pannuti, A R Di Marco, A P Rossi, et al.
Minerva Medica|September 1, 1980
[Urinary hydroxyproline in advanced breast carcinoma and response to treatment with medroxyprogesterone acetate (MAP) in high doses]A Martoni, G Pedelini, G Colalongo, et al.
Panminerva Medica|January 1, 1981
Monochemotherapy (Adriamycin) for metastatic breast cancer in progression after sequential hormone-chemotherapy (MAP and CMF). Pilot studyF Pannuti, A P Rossi, A R Di Marco, et al.
Panminerva Medica|January 1, 1983
The prevention of the cardiotoxic effects of adriamycin by means of strophanthin. Preclinical study (chick embryo test)F Pannuti, E Piana, D Palenzona, et al.
Molecular and Cellular Endocrinology|January 13, 2001
Technical aspects of oocyte cryopreservationR Fabbri, E Porcu, T Marsella, et al.
European Journal of Cancer|April 1, 1979
Prospective, randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancerF Pannuti, A Martoni, A R Di Marco, et al.
Pageof 2